共 8 条
[1]
Prevalence of diag-nosed atrial fibrillation in adults;national implications forrhythm management and stroke prevention;the anticoagu-la-tion and risk factors in atrial fibrillation(ATRIA)stud-y. Go AS,Hylek EM,Philips JA,et al. The Journal of The American Medical Association . 2001
[2]
ximerlagatran versus warfa-rin for stroke prevention in patients with nonvalvular atrialfibrillation SPORTIFⅡ:a dose-guiding,tolerability andsafety. Petersen P,Grind M,Adler J. Journal of the American College of Cardiology . 2003
[3]
The effect of low-dose warfarin on therisk of stroke in patients with nonrheumatic atrial fibrilla-tion. The Bosten Area Anticoagulation Trial for Atrial Fibrilla-tion Investigators. The New England Journal of Medicine . 1990
[4]
Atrial fibrillation as anindependent risk factor for stroke:the framingham study. Wolf PA,Abbott RD,Kannel WB. Stroke . 1991
[5]
Canadian atrialfibrillation anticoagulation(CAFA)study. Connolly SJ,Laupacis A,Gent M,et al. Journal of the American College of Cardiology . 1991
[6]
Riskfactors for thromboembolism during aspirin therapy in pa-tients with atrial fibrillation:the stroke prevention in atrialfibrillation study. Stroke Prevention in Atrial Fibrillation Investigators. Journal of Stroke and Cerebrovascular Diseases . 1995
[7]
Wafarin in theprevention of stroke associated with nonrheumatic atrial fi-brillation. Ezekowitz MD,Bridgers SL,James KE,et al. The New England Journal of Medicine . 1992
[8]
Validation ofclinical classification schemes for predicting stroke:resultsfrom the national registry of atrial fibrillation. Gage BF,Waterman AD,Shannon W,et al. The Journal of The American Medical Association . 2001